Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04394858 · ClinicalTrials.gov registry record · Phase 2
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
A Phase 2 study of Metastatic Adrenal Gland Pheochromocytoma and Metastatic Paraganglioma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 20
- Study locations
NCT04394858 is a Phase 2 study of Metastatic Adrenal Gland Pheochromocytoma and Metastatic Paraganglioma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT04394858, a Phase 2 study of Metastatic Adrenal Gland Pheochromocytoma and Metastatic Paraganglioma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Poly (adenosine diphosphate \[ADP\]-ribose) polymerases (PARPs) are proteins that help repair deoxyribonucleic acid (DNA) mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib with temozolomide may shrink or stabilize the cancer in patients with pheochromocytoma or paraganglioma better than temozolomide alone.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- PROCEDURE Magnetic Resonance Imaging
- DRUG Olaparib
- PROCEDURE Computed Tomography with Contrast
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Idaho
- Saint Luke's Cancer Institute - Boise - Boise
- Saint Luke's Cancer Institute - Fruitland - Fruitland
- Saint Luke's Cancer Institute - Meridian - Meridian
- Saint Luke's Cancer Institute - Nampa - Nampa
- Saint Luke's Cancer Institute - Twin Falls - Twin Falls
Illinois
- Illinois CancerCare-Bloomington - Bloomington
- Illinois CancerCare-Canton - Canton
- Illinois CancerCare-Carthage - Carthage
- Centralia Oncology Clinic - Centralia
Florida
- Holy Cross Hospital - Fort Lauderdale
- UF Health Cancer Institute - Gainesville - Gainesville
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2028-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04394858
The ClinicalTrials.gov registry entry for NCT04394858 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Metastatic Adrenal Gland Pheochromocytoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT04394858 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Alaska, Idaho, Illinois.
Frequently Asked Questions
What is clinical trial NCT04394858 about?
NCT04394858 is a clinical study titled "Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer". This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot ...
What is the current status of trial NCT04394858?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2021-03-17. Estimated completion is 2028-03-01.
What conditions does trial NCT04394858 study?
This clinical trial studies the following conditions: Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8.
What interventions are being tested in trial NCT04394858?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Magnetic Resonance Imaging (PROCEDURE), Olaparib (DRUG), Computed Tomography with Contrast (PROCEDURE).
Who is sponsoring clinical trial NCT04394858?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04394858 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Adrenal Gland Pheochromocytoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Adrenal Gland Pheochromocytoma
All registered trials for this condition
Metastatic Paraganglioma
All registered trials for this condition
Alaska
All trials with a study site in Alaska
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.